Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

Market Cap	31.22B
Revenue (ttm)	5.53B
Net Income (ttm)	1.34B
Shares Out	2.23B
EPS (ttm)	0.60
PE Ratio	23.36
Forward PE	20.17
Dividend	0.27 (2.31%)
Ex-Dividend Date	May 22, 2024

Volume	399,750,454
Average Volume	36,149,328
Open	12.05
Previous Close	11.68
Day's Range	12.00 - 14.02
52-Week Range	10.41 - 16.58
Beta	0.19
RSI	73.43
Earnings Date	Apr 22, 2025

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd. engages in the research and development, and industrialization of biological fermentation technology in China. It offers antibiotic intermediates, such as erythromycin thiocyanate, penicillin G potassium salt, 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodesacetoxycephalosporanic acid, desacetyl-7-aminocephalosporanic acid, and ursodeoxycholic acid. Yili Chuanning Biotechnology Co.,Ltd. was incorporated in 2010 and is based in Yining, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,184
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301301

Financial Performance

In 2024, SHE:301301's revenue was 5.76 billion, an increase of 19.38% compared to the previous year's 4.82 billion. Earnings were 1.40 billion, an increase of 48.88%.